Last reviewed · How we verify
Lansoprazole 15 mg
At a glance
| Generic name | Lansoprazole 15 mg |
|---|---|
| Also known as | non-administered army |
| Sponsor | HK inno.N Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old (PHASE2)
- A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old (PHASE2)
- Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer (PHASE3)
- The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection (PHASE3)
- Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment (NA)
- A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121 (PHASE1)
- Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer (PHASE3)
- Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lansoprazole 15 mg CI brief — competitive landscape report
- Lansoprazole 15 mg updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI